Evaluation of Treatment Success Rate Among Antihyperuricemic Using Real-World Data

被引：0

作者：

Teramoto, Kei ^{[1
]}

Takeda, Toshihiro ^{[2
]}

Matsumura, Yasushi ^{[2
]}

Ohtahara, Akira ^{[3
]}

Hisatome, Ichiro ^{[4
]}

Kondoh, Hiroshi ^{[1
]}

机构：

[1] Tottori Univ Hosp, Div Med Informat, 36-1 Nishi Cho, Tottori 6838504, Japan

[2] Osaka Univ, Med Informat, Grad Sch Med, Osaka, Japan

[3] San In Rosai Hosp, Div Cardiol, Tottori, Japan

[4] Tottori Univ, Inst Regenerat Med & Biofunct, Dept Genet Med & Regenerat Therapeut, Div Regenerat Med & Therapeut,Grad Sch Med Sci, Yonago, Tottori, Japan

来源：

MEDINFO 2019: HEALTH AND WELLBEING E-NETWORKS FOR ALL | 2019年 / 264卷

关键词：

Electronic health records; Pharmacoepidemiology; Antihyperuricemics;

D O I：

10.3233/SHTI190385

中图分类号：

TP39 [计算机的应用];

学科分类号：

081203 ; 0835 ;

摘要：

In this study, treatment and the serum uric acid (UA) level were compared using medication history generated by prescription order records of antihyperuricemic to examine the treatment success rate. We examined the treatment success rate among these patients based on the serum UA level during 120-180 days after the initiation of treatment, which was set as the endpoint. The number of patients whose UA level before the start of treatment was > 8.0 mg/dL but decreased to < 6.0 mg/dL after the treatment, which is the target treatment success, was 92 (success rate of 14.2%), 50 (53.2%), 76 (41.5%), 35 (31.9%), and 45 (37.8%) in the allopurinol 100 mg/day (A1) and 200 mg/day (A2), febuxostat 10 mg/day (F1) and 20 mg/day (F2), and benzbromarone 50 mg/day (B), respectively. Compared with that of the other drugs, the treatment success rate was high with A2 and low with A1. From the generated medication history, the treatment success rate with antihyperuricemic can be extracted mechanically.

引用

页码：1051 / 1055

页数：5

共 50 条

[31] Secure Messaging Use Among Patients with Depression: An Analysis Using Real-World Data
Ko, Seung-Min A.
Warm, Eric J.
Schauer, Daniel P.
Ko, Dong-Gil
TELEMEDICINE AND E-HEALTH, 2024, 30 (08) : 2157 - 2164
[32] From real-world electronic health record data to real-world results using artificial intelligence
Knevel, Rachel
Liao, Katherine P.
ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 (03) : 306 - 311
[33] Conundrum of Using Real-World Observational Data to Inform Real-World Conclusions About Safety and Efficacy
Gibson, C. Michael
Nafee, Tarek
Kerneis, Mathieu
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 72 (15) : 1801 - 1803
[34] Use of immunosuppressive therapy among patients with NMOSD using satralizumab treatment: A study based on Japanese real-world data
Nakahara, Jin
Nakashima, Ichiro
Yasunaga, Hideo
Yamashita, Masami
Nishijima, Nobuo
Satomura, Atsushi
Nio, Mariko
Fujihara, Kazuo
MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 1004 - 1004
[35] Prediction of treatment nonadherence among older adults with chronic obstructive pulmonary disease using Medicare real-world data
Le, Tham T.
Bjarnadottir, Margret
Qato, Danya M.
Magder, Larry
Zafari, Zafar
Simoni-Wastila, Linda
JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2022, 28 (06): : 631 - 644
[36] Editorial: Real-world data and real-world evidence in lung cancer
Gristina, Valerio
Eze, Chukwuka
FRONTIERS IN ONCOLOGY, 2024, 14
[37] Inaccurate Real-World Data Does Not Provide Real-World Answers
Buffet, Gabriela
Mendoza-Sassi, Raul
Fysekidis, Marinos
AMERICAN JOURNAL OF THERAPEUTICS, 2021, 28 (05) : E596 - E598
[38] For insights into the real world, consider real-world data
Raoof, Sana
Kurzrock, Razelle
SCIENCE TRANSLATIONAL MEDICINE, 2022, 14 (673)
[39] Editorial: Real-world data and real-world evidence in hematologic malignancies
Malagola, Michele
Ohgami, Robert
Greco, Raffaella
FRONTIERS IN ONCOLOGY, 2023, 13
[40] When can real-world data generate real-world evidence?
Rahman, Motiur
Dal Pan, Gerald
Stein, Peter
Levenson, Mark
Kraus, Stefanie
Chakravarty, Aloka
Rivera, Donna R.
Forshee, Richard
Concato, John
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2024, 33 (01)

← 1 2 3 4 5 →